ArticleMolecular therapy. Nucleic acids2026
Spleen-targeted mRNA delivery via long-chain PEGylated lipids at low molar ratio enhances antitumor immunity against melanoma.
Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Delivering the future of immunotherapy: A state-of-the-art review of gene editing in immune cells with lipid nanoparticles.Materials today. Bio · 2026Review
- mRNA cancer vaccines: delivery strategies, immune modulation, and clinical translation.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid nanoparticles (LNPs) are pivotal for mRNA delivery, yet predominant hepatic accumulation limits their therapeutic application in immunologically active sites like the spleen. Engineering LNPs for splenic mRNA delivery is therefore essential for advancing mRNA-based immunotherapies. Here, we rationally designed a series of LNPs by modulating the alkyl chain length of PEGylated lipids (fast-shedding C14 DMG-PEG vs. slow-shedding C18 DSG-PEG) and their molar ratios (0.75% and 1.5%). This systematic variation precisely controlled nanoparticle physicochemical properties and protein corona composition. Among these formulations, DSG-PEG LNPs at 0.75% mol exhibited the largest size (∼170 nm by DLS; ∼60 nm core by cryo-EM) and a distinct protein corona. Notably, this DSG-PEG 0.75% mol formulation demonstrated significantly enhanced selective spleen accumulation and efficient mRNA delivery
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.